The Annals of pharmacotherapy
-
To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease. ⋯ Sacituzumab govitecan is a novel targeted treatment with promising activity in mTNBC.